Vaxcyte appoints CMO and CLO; narrows VAX-31 OPUS-1 topline data to end of October 2026

Vaxcyte, Inc.

Luis Jodar, Ph.D., former Pfizer CMO for Vaccines and Infectious Diseases, joins as Chief Medical Officer.
David McAvoy, J.D., former Teva Chief Legal Officer, joins as Chief Legal Officer; Mikhail Eydelman remains SVP, General Counsel.
Topline safety, tolerability, and immunogenicity data from VAX-31 Phase 3 OPUS-1 trial now expected by end of October 2026, narrowing prior Q4 guidance.
Jodar led clinical development and medical affairs for Prevnar 13 and Prevnar 20 at Pfizer.

Featured in Daily 8-K Digest

Selected #1 for 2026-09-03. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.